Key
Executive Summary
Theo-Dur sales in the U.S. grew 43% in 1983 to $65 mil., with Theo-Dur Sprinkle contributing another $4 mil. in sales last year, the firm said in its annual report for 1983. Together, the two Theo-Dur products increased their share of the xanthine bronchodilator market from 29% to 40%, Key noted. The firm reported that Nitro-Dur sales increased 80% in 1983 to $48 mil.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.